Laboratory Test Preparation

• HBV Genotyping
• Hepatitis B - Anti-viral resistance profile - serum

Not Applicable

To determine genotype of Hepatitis B Virus. Determining the genotype of the particular virus can be useful for predicting efficacy and for deciding which drugs and what dose to prescribe.

Sequencing

Special Test

• No patient preparation necessary.
• Please specify the date and result of the last viral load.
• Less than 15 days prior to sample collection for Genotyping is required.
• The test will only be performed if the viral load has recently been performed. Please ensure you enclose the result of the recent viral load test.
• The minimum viral load is 1000 copies/mL (180 IU)

Red or Gold Tube (2pcs)

6 mL of Serum

Not Applicable

24 Hours

7 Days

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Over-filled or Under-filled tube
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used
• Hemolyzed Specimen

Batch Running

Friday, 12:00 PM

2 months after cut-off (excluding Saturdays, Sundays and Holidays)

Not Applicable

None Specified

Not Applicable

HBV Tests, Hep B, anti-HBs, Hepatitis B Surface Antibody, HBsAg, Hepatitis B Surface Antigen, HBeAg, Hepatitis B e Antigen, anti-HBc, Hepatitis B Core Antibody, anti-HBc, IgM, anti-Hbe, Hepatitis B e Antibody, HBV DNA, Hepatitis B Virus Testing

Not applicable

•HbsAg with Titer (CMIA)
•Anti HBs (CMIA)
•HBeAg (CMIA)
•Anti HBe (CMIA)
•Anti HBc Total (CMIA)
•Anti HBc IgM (CMIA)
•Anti HAV IgG (CMIA)
•Anti HAV IgM (CMIA)

Used to assess phase of Hepatitis B infection and screen for Hepatitis A.

Chemiluminescent Microparticle Immunoassay (CMIA)

Immunology

No patient preparation necessary.

Red or Gold tube

3-5 mL Serum

3-5 mL Plasma (Na-citrate, K-EDTA, Na-Heparin)

Not specified

7 Days

3 Freeze-Thaw cycles

Transport specimen at 2°C – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic sample
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Tuesday, Wednesday, Thursday, Friday, Saturday

Monday to Saturday:10:00 PM

Sunday:6:00PM

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

See individual tests

• Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits that employ mouse monoclonal antibodies.
• Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed.
• Specimens from patients with high levels of IgM, e.g. specimens from patients with multiple myeloma, may show depressed values when tested with assay kits that use reagents containing antihuman IgM.

Not applicable

HAV-Ab IgM; HAV-Ab IgG; HAV-Ab total; Anti-HAV, Viral Hepatitis A Antibody, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus Testing

Not applicable

•HbsAg with Titer (CMIA)
•Anti HBs (CMIA)
•HBeAg (CMIA)
•Anti HBe (CMIA)
•Anti HBc Total (CMIA)
•Anti HBc IgM (CMIA)
•Anti HAV IgG (CMIA)
•Anti HAV IgM (CMIA)
•Anti HCV (CMIA)

Used to assess phase of Hepatitis B infection and screen for Hepatitis A & C.

Chemiluminescent Microparticle Immunoassay (CMIA)

Immunology

No patient preparation necessary.

Red or Gold tube

3-5 mL Serum

3-5 mL Plasma (Na-citrate, K-EDTA, Na-Heparin)

Not specified

7 Days

3 Freeze-Thaw cycles

Transport specimen at 2°C – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic sample
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Tuesday, Wednesday, Thursday, Friday, Saturday

Monday to Saturday:10:00 PM

Sunday:6:00PM

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

See individual tests

• Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits that employ mouse monoclonal antibodies.
• Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed.
• Specimens from patients with high levels of IgM, e.g. specimens from patients with multiple myeloma, may show depressed values when tested with assay kits that use reagents containing antihuman IgM.

Not applicable

HAV-Ab IgM; HAV-Ab IgG; HAV-Ab total; Anti-HAV, Viral Hepatitis A Antibody, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus Testing, Hepatitis C Antibody; Anti-HCV; HCV-PCR; HCV-RNA; Hepatitis C Viral LoadViral Hepatitis C Antibody Screen; Viral Hepatitis C RNA by PCR; Hepatitis C Virus Genotype

Not applicable

•HbsAg with Titer (CMIA)
•Anti HBs (CMIA)
•HBeAg (CMIA)
•Anti HBe (CMIA)
•Anti HBc Total (CMIA)
•Anti HBc IgM (CMIA)

Used to assess phase of Hepatitis B infection, example, if infectious and/or recovery phase.

Chemiluminescent Microparticle Immunoassay (CMIA)

Immunology

No patient preparation necessary.

Red or Gold tube

3-5 mL Serum

3-5 mL Plasma (Na-citrate, K-EDTA, Na-Heparin)

Not specified

7 Days

3 Freeze-Thaw cycles

Transport specimen at 2°C – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic sample
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Tuesday, Wednesday, Thursday, Friday, Saturday

Monday to Saturday:10:00 PM

Sunday:6:00PM

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

See individual tests

• Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits that employ mouse monoclonal antibodies.
• Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed.
• Specimens from patients with high levels of IgM, e.g. specimens from patients with multiple myeloma, may show depressed values when tested with assay kits that use reagents containing antihuman IgM.

Not applicable

Hepatitis B, HBV, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus Testing

Not applicable

•HbsAg with Titer (CMIA)
•Anti HBs (CMIA)

Used to screen for Hepatitis B and if patient needs vaccine/booster for Hepatitis B.

Chemiluminescent Microparticle Immunoassay (CMIA)

Immunology

No patient preparation necessary.

Red or Gold tube

1-3 mL Serum

1-3mL Plasma (Na-citrate, K-EDTA, Na-Heparin)

Not specified

7 Days

3 Freeze-Thaw cycles

Transport specimen at 2°C – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic sample
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Daily

Monday to Saturday:10:00 PM

Sunday:6:00PM

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

See individual tests

• Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits that employ mouse monoclonal antibodies.
• Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed.

Not applicable

HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus Testing

• HCV - genotyping
• Genotyping - HCV
• HCV - genotyping

Not Applicable

Hepatitis C is a viral infection that causes inflammation of the liver.

Genotype is a predictor of the outcome of anti-HCV therapy with interferon based treatment regimens.

Genotype is also helped to determine treatment.

Real-Time Polymerase Chain Reaction (RT-PCR)

Special Test

• No patient preparation necessary.
• The test will only be performed if the viral load has recently been performed. Please ensure you enclose the result of the recent viral load test.
• The minimum viral load to proceed with testing is 500 IU/mL

Red or Gold Top

4 mL Serum

Not Applicable 

24 Hours

5 Days

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used
• Clotted specimen

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Not Applicable

None Specified

Not Applicable

Hepatitis C Antibody, Anti-HCV, HCV-PCR, HCV-RNA, Hepatitis C Viral Load, Viral Hepatitis C Antibody Screen, Viral Hepatitis C RNA by PCR, Hepatitis C Virus Genotype

• HDV RNA
• RNA - HDV
• HDV RNA
• Hepatitis Delta - viral load - PCR

Not Applicable

Hepatitis Delta Virus (HDV) is a defective RNA virus which depends on certain functions of the hepatitis B virus for its replication. Therefore, HDV infection is only possible in subjects simultaneously or previously infected with HBV. The HDV antigen is usually detectable over a period of one week to one month during the acute phase. HDV-specific IgM antibodies can be detected 2 to 5 weeks after the beginning of the infection and sometimes this is the only evidence. In chronic infection, these IgM antibodies sometimes persist. A positive anti-HDV antibody test result is evidence of previous exposure to the virus. Now, a PCR-based assay for HDV RNA is available to measure viral activity.

Real-Time Polymerase Chain Reaction (RT-PCR)

Special Test

• No patient preparation necessary.
• Ask for the Information Note Form (N23-INTGB) at Special Test Section atleast one day prior submission of sample.
• For Special Test:  S14UK transport bag is Mandatory.

Red or Gold Tube

3 mL Serum

Not Applicable

24 Hours

5 Days

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Batch Running

Friday, 12:00 PM

3 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Not Applicable

None Specified

Not Applicable

HBV Tests, Hep B, anti-HBs, Hepatitis B Surface Antibody, HBsAg, Hepatitis B Surface Antigen, HBeAg, Hepatitis B e Antigen, anti-HBc, Hepatitis B Core Antibody, anti-HBc, IgM, anti-Hbe, Hepatitis B e Antibody, HBV DNA, Hepatitis B Virus Testing

• HDV - IgM antibodies
• Anti-HDV IgM antibodies
• D hepatitis
• HDV - IgM antibodies
• Delta hepatitis

Not Applicable

•  HDV (or hepatitis delta virus) is a defective RNA virus which depends on certain functions of the hepatitis B virus for its replication. Therefore, HDV infection is only possible in subjects simultaneously or previously infected with HBV. The HDV antigen is usually detectable over a period of one week to one month during the acute phase. HDV-specific IgM antibodies can be detected 2 to 5 weeks after the beginning of the infection and sometimes this is the only evidence. In chronic infection, these IgM antibodies sometimes persist. A positive total anti-HDV antibody test result is evidence of previous exposure to the virus. Now, a PCR-based assay for HDV RNA is available to measure viral activity.

Enzyme-immunoassay

Special Test

No patient preparation necessary.

Red or Gold Tube

3 mL Serum

Not Applicable

24 Hours

5 Days

30 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Available upon request

None Specified

Not Applicable

HBV Tests, Hep B, anti-HBs, Hepatitis B Surface Antibody, HBsAg, Hepatitis B Surface Antigen, HBeAg, Hepatitis B e Antigen, anti-HBc, Hepatitis B Core Antibody, anti-HBc, IgM, anti-Hbe, Hepatitis B e Antibody, HBV DNA, Hepatitis B Virus Testing

• Total anti-HDV antibodies
• Delta Hepatitis
• HDV - Total Antibodies
• D Hepatitis

Not Applicable

Hepatitis D Virus (HDV) infection occurs in association with HBV infection. A positive result for HDV total antibody may indicate either acute or chronic HDV infection.HDV (or hepatitis delta virus) is a defective RNA virus which depends on certain functions of the hepatitis B virus for its replication. Therefore, HDV infection is only possible in subjects simultaneously or previously infected with HBV. The HDV antigen is usually detectable over a period of one week to one month during the acute phase. HDV-specific IgM antibodies can be detected 2 to 5 weeks after the beginning of the infection and sometimes this is the only evidence. In chronic infection, these IgM antibodies sometimes persist. A positive total anti-HDV antibody test result is evidence of previous exposure to the virus. Now, a PCR-based assay for HDV RNA is available to measure viral activity.

Enzyme Immunoassay (EIA)

Special Test

No patient preparation necessary.

Red or Gold Tube

3 mL Serum

Not Applicable

24 Hours

5 Days

30 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Available upon request

None Specified

Not Applicable

HBV Tests, Hep B, anti-HBs, Hepatitis B Surface Antibody, HBsAg, Hepatitis B Surface Antigen, HBeAg, Hepatitis B e Antigen, anti-HBc, Hepatitis B Core Antibody, anti-HBc, IgM, anti-Hbe, Hepatitis B e Antibody, HBV DNA, Hepatitis B Virus Testing

• HEV - IgG antibodies
• Oro-fecal transmission
• Enteral transmission
• HEV - IgG antibodies
• Anti-HEV antibodies - IgG
• E hepatitis

Not Applicable

Hepatitis E virus (HEV) belongs to the Calcivirus family. It is a polyadenylated single-strand RNA non-enveloped virus. Its epidemiology is similar to that of hepatitis A: transmission by the faecal-oral route and incidence in epidemic or sporadic form. The incubation period is 15 to 64 days. The disease is not endemic in Western Europe or North America. The cases described consist of travellers having stayed in endemic areas (Indies, Central and North Africa, Peru, Mexico, China, Nepal, Russia, Pakistan). The clinical profile is comparable to that of Hepatitis A. Cases generall progress towards recovery, with no chronic form or progression to hepatocarcinoma. High mortality in pregnant women

Enzyme-immunoassay (EIA)

Special Test

No patient preparation necessary.

Red or Gold Tube

3 mL Serum

Not Applicable

24 Hours

5 Days

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Available upon request

None Specified

Not Applicable

Provide at least short-term protection against disease.

• HEV - IgM antibodies
• Anti-HEV IgM antibodies
• oro-fecal transmission
• enteral transmission
• E hepatitis
• HEV - IgM antibodies

Not Applicable

Hepatitis E causes an acute, self-limiting infection. Antibody IgG is detected after Antibody IgM is detected, typically 1 month post-infection. Antibody IgM is detected 1-4 weeks post-infection.

Hepatitis E Virus (HEV) is the major etiologic agent of enterically transmitted non-A, non-B hepatitis worldwide and has a high case-fatality rate in pregnant women. Both IgM and IgG antibody to HEV (anti-HEV) are produced following infection. The titer of IgM anti-HEV declines rapidly during early convalescence; IgG anti-HEV persists and appears to provide at least short-term protection against disease

Enzyme-immunoassay (EIA)

Special Test

No patient preparation necessary.

Red or Gold Tube

3 mL Serum

Not Applicable

24 Hours

5 Days

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic sample
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Available upon request

None Specified.

Not Applicable

Liver inflammation

HEP E RNA

Not Applicable

Hepatitis E Virus (HEV) is the major etiologic agent of enterically transmitted non-A, non-B hepatitis worldwide and has a high case-fatality rate in pregnant women. Both IgM and IgG antibody to HEV (anti-HEV) are produced following infection. The titer of IgM anti-HEV declines rapidly during early convalescence; IgG anti-HEV persists and appears to provide at least short-term protection against disease.

Polymerase Chain Reaction (PCR)

Special Test

• No patient preparation necessary.
• Sample must be sent to laboratory immediately after collection at 2-8°C
• Samples that cannot be sent to HPD laboratory within 4 hours should be stored at -20°C and should be transported with dry ice.
• Ask for the Information Note Form (N23-INTGB) at Special Test Section atleast one day prior submission of sample.
• For Special Test:  S14UK transport bag is Mandatory.

EDTA or Violet Tube

3 mL Plasma

Not Applicable

Not Applicable

4 Hours

28 Days

Transport specimen at 2 – 8 °C (with cold packs)

• Hemolyzed specimen
• Markedly lipemic specimen
• Exceeded sample stability requirement
• Quantity not sufficient
• Improperly labeled specimen
• Improper collection tube used
• Clotted Specimen

Batch Running

Friday, 12:00 PM

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Not Applicable

None Specified

Not Applicable

Small virus with positive sense, Single stranded ribonucleic acid genome

• Liver
• Common Bile Duct
• Gall Bladder
• Pancreas

PREPARATION

• No food intake for at least 6 hours.
• NOTE: No need to fast if patient has undergone cholecystectomy or surgical removal of gall bladder.

• Drinking of water is not prohibited.
• Bring previous ultrasound result for comparison.

-

-

-

HER2 FISH

Not Applicable

- Used to quantitatively determine amplification of the HER2/NEU gene in formalin-fixed paraffin-embedded (FFPE) breast cancer tissue.

- Serves as a companion diagnostic for identifying breast cancer patients who may be eligible for treatment with Herceptin.

Fluorescence in-situ hybridization (FISH)

Histopathology

All samples must be LABELED properly and legibly. The label must match the information on the test request form and on the provided Histopathology and Immunohistochemistry Reports.

- Microscope slides should be placed in slide holders or mailers and should be adequately padded before placing in a shipping/packaging container to prevent breakage.

- FFPE tissue blocks must be placed in a box and avoid direct sunlight to prevent melting and disorientation during transport or shipping.

- Formalin-fixed paraffin-embedded (FFPE) breast cancer tissue block

- 1 H&E stained slide representative of the submitted tissue block

- One IHC (Immunohistochemistry) Her2/Neu slide

- Histopathology report for the submitted tissue slide and block

- IHC (Immunohistochemistry) report of the submitted tissue slide and block

Note:

Please ensure that HPD Histopathology Request Form (HPD_F_258) is completely filled out.

Not applicable

- FFPE tissue blocks and H&E slides are stable indefinitely when stored properly at   room temperature (15^oC - 30^oC).

- Hi-Precision Diagnostics will store FFPE tissue blocks and H&E slides for 10 years, after which samples will be disposed properly according to biosafety disposal guidelines.

Formalin-Fixed Paraffin Embedded (FFPE) tissue blocks - indefinite

Not applicable

Unacceptable

- Transport at room temperature (15 °C – 30 °C)

- Avoid exposure to direct sunlight.

- Keep samples dry.

- FFPE tissue blocks other than breast cancer tissue

- Inadequate tissue available on the tissue block

- Improper or insufficient labeling of tissue blocks or slides

- Incomplete documents/forms submitted

Upon completion of batch of 3 samples

12:00 noon

14 working days excluding Saturdays, Sundays and Holidays

- HER2 signal not detected:  INDETERMINATE; additional testing or specimen may be required.

- HER2/CEP17 ratio < 2.0:  NEGATIVE for HER2 amplification; Patient is NOT eligible for HER2-targeted therapy

- HER2/CEP17 ratio > 2.0:  POSITIVE for HER2 amplification; Patient is eligible for HER2-targeted therapy

The following factors may affect the outcome of your results:

- Cold ischemic time over 1 hour

- Duration of fixation over 72 hours

- Fixation in non-formalin fixatives

Q: What is HER2?

A:HER2 is a gene that, when overexpressed, plays an important role in the development and progression of certain types of breast cancer.

Q: I feel/have a lump in my breast. Will this test tell me if I have cancer?

A:No, it won’t. You will need to have your doctor check whether that lump in your breast is malignant or not.

Q: I am male and have breast cancer. Will I benefit from this test?

A:Yes.

Q: What is Herceptin?

A:Herceptin is a monoclonal antibody that is designed to target HER2.

Q: Why do I need to be HER2 positive to be eligible for Herceptin treatment?

A:Herceptin works by attaching itself to HER2. Only cancer cells with overamplified HER2 will benefit from Herceptin. Moreover, Herceptin is expensive and toxic to your cells. Taking Herceptin if you don’t really need it could lead to a potentially toxic, costly and ineffective therapy.

Q: I’m HER2 positive, but I can’t afford Herceptin. Can I be treated with drug X instead?

A:HER2 positive breast cancer is associated with a more aggressive disease, poorer patient outcome and decreased survival. Treatment with Herceptin has shown a significant clinical benefit. Treatment with other types of drugs will not give similar clinical outcome.

Companion diagnostic for Herceptin, Targeted therapy for breast cancer, Fluorescence In Situ Hybridization, breast Cancer, HER2, HER2 gene

• Herpes simplex virus 1 and 2 IgG (CLIA)
• HSV 1/2 IgG (CLIA)

Not Applicable

Used for the qualitative determination of specific IgG antibodies to Herpes Simplex Virus Type 1 and 2 in human serum or plasma samples

Flow Immunofluorimetry

special test 

No special patient preparation

Red / Gold top

3 mL Serum

Not applicable

7 days

>7 days

Store and transport specimen at 2⁰C to 8⁰C (with cold packs).

• Improperly labeled specimens
• Hemolyzed specimens
• Lipemic specimens
• Quantity not sufficient
• Specimen storage and transport exceeded required temperature

Batch Running 

Friday, 12:00 PM

2 weeks after after cut-off( except Saturday, Sundays and Holidays)

Bacterial contamination or heat inactivation of the specimen may affect the test results.

Not Applicable

Herpes Culture, Herpes Simplex Viral Culture, HSV DNA, HSV by PCR, HSV-1 or HSV-2 IgM, HHV1, HHV2